Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference
Arcellx (NASDAQ: ACLX), a biotechnology company focused on developing innovative immunotherapies for cancer and other incurable diseases, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. The company's management will engage in a fireside chat scheduled for Wednesday, March 5, at 1:10 p.m. ET.
Investors and interested parties can access a live webcast of the discussion through the Investors section of Arcellx's website at www.arcellx.com. The webcast recording will remain available for replay on the company's website for 30 days after the event.
Arcellx (NASDAQ: ACLX), una società biotecnologica focalizzata sullo sviluppo di immunoterapie innovative per il cancro e altre malattie incurabili, ha annunciato la sua prossima partecipazione alla 45a Conferenza Annuale sulla Salute di TD Cowen. Il management dell'azienda parteciperà a una chiacchierata informale programmata per mercoledì 5 marzo, alle 13:10 ET.
Investitori e parti interessate possono accedere a una trasmissione in diretta della discussione attraverso la sezione Investitori del sito web di Arcellx all'indirizzo www.arcellx.com. La registrazione della trasmissione rimarrà disponibile per la riproduzione sul sito dell'azienda per 30 giorni dopo l'evento.
Arcellx (NASDAQ: ACLX), una empresa biotecnológica centrada en el desarrollo de inmunoterapias innovadoras para el cáncer y otras enfermedades incurables, ha anunciado su próxima participación en la 45ª Conferencia Anual de Salud de TD Cowen. La dirección de la empresa participará en una charla informal programada para miércoles 5 de marzo, a la 1:10 p.m. ET.
Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la discusión a través de la sección de Inversores del sitio web de Arcellx en www.arcellx.com. La grabación de la transmisión estará disponible para su reproducción en el sitio de la empresa durante 30 días después del evento.
Arcellx (NASDAQ: ACLX)는 암 및 기타 불치병을 위한 혁신적인 면역 요법 개발에 중점을 둔 생명공학 회사로, TD Cowen 제45회 연례 건강 관리 회의에 곧 참여할 것이라고 발표했습니다. 회사의 경영진은 3월 5일 수요일, 오후 1시 10분 ET에 예정된 대화에 참여할 것입니다.
투자자 및 관심 있는 당사자는 Arcellx 웹사이트의 투자자 섹션을 통해 논의의 생중계를 시청할 수 있습니다. 생중계 녹화는 이벤트 후 30일 동안 회사 웹사이트에서 재생할 수 있습니다.
Arcellx (NASDAQ: ACLX), une entreprise de biotechnologie axée sur le développement d'immunothérapies innovantes pour le cancer et d'autres maladies incurables, a annoncé sa prochaine participation à la 45e Conférence Annuelle sur la Santé de TD Cowen. La direction de l'entreprise participera à une discussion informelle prévue pour mercredi 5 mars, à 13h10 ET.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la discussion via la section Investisseurs du site web de Arcellx à l'adresse www.arcellx.com. L'enregistrement du webinaire sera disponible en replay sur le site de l'entreprise pendant 30 jours après l'événement.
Arcellx (NASDAQ: ACLX), ein biotechnologisches Unternehmen, das sich auf die Entwicklung innovativer Immuntherapien für Krebs und andere unheilbare Krankheiten konzentriert, hat seine bevorstehende Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Das Management des Unternehmens wird an einem informellen Gespräch teilnehmen, das für Mittwoch, den 5. März, um 13:10 Uhr ET geplant ist.
Investoren und Interessierte können über den Investor-Bereich der Website von Arcellx unter www.arcellx.com auf einen Live-Stream der Diskussion zugreifen. Die Aufzeichnung des Live-Streams wird 30 Tage nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event.
About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx's mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. For more information on Arcellx, please visit www.arcellx.com. Follow Arcellx on X @arcellx and LinkedIn.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including Arcellx's expectations regarding the timing and outcomes of clinical trials for its product candidates and the potential impact of its product candidates and platforms on patients and cell therapy. The forward-looking statements contained herein are based upon Arcellx's current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including risks that may be found in the section entitled “Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the Securities and Exchange Commission (SEC) on November 7, 2024, and other documents that Arcellx files from time to time with the SEC. These forward-looking statements are made as of the date of this press release, and Arcellx assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250226837610/en/
Investor Contact:
Myesha Lacy
ir@arcellx.com
510-418-2412
Media Contact:
Andrea Cohen
Sam Brown Inc.
andreacohen@sambrown.com
917-209-7163
Source: Arcellx, Inc.
FAQ
When is Arcellx (ACLX) presenting at the TD Cowen Healthcare Conference?
How can investors watch Arcellx's (ACLX) TD Cowen conference presentation?
How long will Arcellx's (ACLX) TD Cowen conference presentation be available for replay?
What type of therapies is Arcellx (ACLX) developing according to the announcement?
